Shattuck Labs Inc Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline HR-MDS and TP53m AML and Review of Dose-Escalation Data from ASH 2023 Annual Meeting Transcript
Good morning and welcome to the Shattuck Labs investor conference call. (Operator Instructions) Later we will conduct a question-and-answer session and instructions will be will follow at that time. As a reminder, this conference call is being recorded. I will now turn the call over to your host, Dr. Taylor Schreiber. Taylor, please go ahead.
&-
Thank you, operator. Good morning, everyone, and thank you for joining. I'm Taylor Schreiber, the Chief Executive Officer and scientific Co-Founder of Shattuck labs. We are excited to provide initial data from the Phase 1B portion of our clinical trial, combining SL-172154 with a decided in in frontline TP53 mutant AML and higher risk MDS patients throughout today's call, I will refer to SL-172154 simply as 154. Press release reporting top line results was issued pre-market this morning and can be found on the Investor Relations section of our website, Jannick labs.com.
Before we begin, I would like to remind you that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
